Article Details

COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP ...

Retrieved on: 2024-10-30 13:59:57

Tags for this article:

Click the tags to see associated articles and topics

COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP .... View article details on hiswai:

Excerpt

... immune tolerance platform and are designed to reprogram the immune system to address the underlying root cause of immune-mediated diseases. Data ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up